Abstract: A method for generating deimmunized antibody therapeutics, including: labeling a plurality of mutated variants of an antibody therapeutic with unique barcodes; providing a plurality of barcode-labeled mutated variants to a population of antibody therapeutic-specific B-cells; allowing the plurality of barcode-labeled mutated variants to bind to the population of antibody therapeutic-specific B-cells; and identifying unbound mutated variants as having lower immunogenicity than the antibody therapeutic.

Abstract: The present disclosure provides antibodies that specifically bind to TIGIT. The antibodies have the capacity for substantial activation of T cells and natural killer cells by inhibiting binding of TIGIT to CD155. The antibodies can be used for treatment of cancer and infectious disease, among other applications.

Abstract: Provided herein are anti-CD39 antibodies that inhibit the enzymatic activity of human CD39 and methods of using the same.

Abstract: Provided herein are anti-CD39 antibodies that inhibit the enzymatic activity of human CD39 and methods of using the same.

Abstract: The present disclosure provides antibodies that specifically bind to TIGIT. The antibodies have the capacity for substantial activation of T cells and natural killer cells by inhibiting binding of TIGIT to CD155. The antibodies can be used for treatment of cancer and infectious disease, among other applications.

Abstract: The present disclosure provides antibodies that specifically bind to TIGIT. The antibodies have the capacity for substantial activation of T cells and natural killer cells by inhibiting binding of TIGIT to CD155. The antibodies can be used for treatment of cancer and infectious disease, among other applications.

Abstract: Disclosed herein are spinal fixation systems that may comprise a screw, a body, and a pressure cap. A screw may comprise a head at a proximal end, a bone connection element at a distal end, and a first mating element disposed on a head of a pedicle screw. A body may comprise a proximal end, a distal end, a mounting rod receiving channel at a proximal end, and a screw head receiving aperture at a distal end. A portion of the mounting rod receiving channel may be operable to receive a compression element. A pressure cap may comprise a proximal end, distal end, and a second mating element on a distal end. A first mating element of the screw may be configured to mate with the second mating element of the pressure cap thereby limiting the pivotal movement of the screw to that of a monoaxial screw.

Abstract: Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.

Abstract: Disclosed herein are spinal fixation systems that may comprise a screw, a body, and a pressure cap. A screw may comprise a head at a proximal end, a bone connection element at a distal end, and a first mating element disposed on a head of a pedicle screw. A body may comprise a proximal end, a distal end, a mounting rod receiving channel at a proximal end, and a screw head receiving aperture at a distal end. A portion of the mounting rod receiving channel may be operable to receive a compression element. A pressure cap may comprise a proximal end, distal end, and a second mating element on a distal end. A first mating element of the screw may be configured to mate with the second mating element of the pressure cap thereby limiting the pivotal movement of the screw to that of a monoaxial screw.

Abstract: A spinal fixation system may comprise a body, a tower, a set screw holder, and a set screw. A body may comprise a saddle, at least two tabs connected to and extending proximally from the saddle, a receiving channel disposed between the at least two tabs, and a securing mechanism, such as internal threads. A tower may comprise a central shaft configured to be received into the receiving channel, a cannula, at least two panels, an enlarged section, and an attachment feature configured to slide proximally and distally between the at least two panels and the enlarged section. A set screw holder may comprise a receiver and an insert. A receiver may comprise a passageway and a set screw engaging feature. The insert may be is sized to be received into the passageway of the receiver and may be configured to engage the set screw engaging feature.

Abstract: Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.

Abstract: A modular head-to-head cross connector or construct extension system comprising a fastener element driven into a bone in a first orientation, a first U-shaped body operable to receive the fastener element and operable to receive a first rod in a first rod receiving channel, and a first compression element driven adjacent to and against the first rod in the first rod receiving channel, thereby engaging the first rod against the fastener element in a second orientation independent of the first orientation of the fastener element. The system further comprises a second U-shaped body operable to receive first compression element and operable to receive a second rod in a second rod receiving channel, and a second compression element driven adjacent to and against the second rod in the second rod receiving channel, thereby engaging the second rod against the first compression element in a third orientation independent of the second orientation.

Abstract: A modular head-to-head cross connector or construct extension system comprising a fastener element driven into a bone in a first orientation, a first U-shaped body operable to receive the fastener element and operable to receive a first rod in a first rod receiving channel, and a first compression element driven adjacent to and against the first rod in the first rod receiving channel, thereby engaging the first rod against the fastener element in a second orientation independent of the first orientation of the fastener element. The system further comprises a second U-shaped body operable to receive first compression element and operable to receive a second rod in a second rod receiving channel, and a second compression element driven adjacent to and against the second rod in the second rod receiving channel, thereby engaging the second rod against the first compression element in a third orientation independent of the second orientation.

Abstract: Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.

Abstract: Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.

Abstract: A modular head-to-head cross connector or construct extension system comprising a fastener element driven into a bone in a first orientation, a first U-shaped body operable to receive the fastener element and operable to receive a first rod in a first rod receiving channel, and a first compression element driven adjacent to and against the first rod in the first rod receiving channel, thereby engaging the first rod against the fastener element in a second orientation independent of the first orientation of the fastener element. The system further comprises a second U-shaped body operable to receive first compression element and operable to receive a second rod in a second rod receiving channel, and a second compression element driven adjacent to and against the second rod in the second rod receiving channel, thereby engaging the second rod against the first compression element in a third orientation independent of the second orientation.

Abstract: Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.

Abstract: Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.

Abstract: Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.

Abstract: Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.